Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Wattel

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
Pageof 10